CCO Oncology Podcast

New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

Episode Summary

Gain insight from expert perspectives on key studies from the Pan Pacific Lymphoma Conference 2022 covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.

Episode Notes

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
• MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
• BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
• BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
• BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL

Presenters: 

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program:
https://bit.ly/3OQ6634